Search research articles
Contact Us
Filters
Showing results (51-60 of 63) with videos related to
Page
of 7
Sort By:
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
September 24, 2011
Cav1.2 L-type Ca²⁺ channels mediate cocaine-induced GluA1 trafficking in the nucleus accumbens, a long-term adaptation dependent on ventral tegmental area Ca(v)1.3 channels
Kathryn Schierberl, Jin Hao, Thomas F Tropea, et al.
International Journal of Molecular Sciences
|
October 27, 2022
Esmethadone (REL-1017) and Other Uncompetitive NMDAR Channel Blockers May Improve Mood Disorders via Modulation of Synaptic Kinase-Mediated Signaling
Stephen M Stahl, Sara De Martin, Andrea Mattarei, et al.
NIH Consensus and State-Of-The-Science Statements
|
March 1, 2008
NIH consensus development statement on hydroxyurea treatment for sickle cell disease
Otis W Brawley, Llewellyn J Cornelius, Linda R Edwards, et al.
Pharmaceuticals (Basel, Switzerland)
|
August 26, 2022
Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors
Ezio Bettini, Stephen M Stahl, Sara De Martin, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
July 2, 2003
A conditional deletion of the NR1 subunit of the NMDA receptor in adult spinal cord dorsal horn reduces NMDA currents and injury-induced pain
Samantha M South, Tatsuro Kohno, Brian K Kaspar, et al.
European Archives of Psychiatry and Clinical Neuroscience
|
March 8, 2023
Esmethadone-HCl (REL-1017): a promising rapid antidepressant
Maurizio Fava, Stephen M Stahl, Sara De Martin, et al.
International Clinical Psychopharmacology
|
February 27, 2026
Depression severity and efficacy outcomes: post hoc analyses from a phase 3 trial of esmethadone for the adjunctive treatment of major depressive disorder with inadequate response to standard antidepressants
Clotilde Guidetti, George I Papakostas, Steven Stahl, et al.
The Journal of Clinical Psychiatry
|
February 25, 2025
Long-Term Safety and Efficacy of Esmethadone in Patients With Major Depressive Disorder: Findings From a 12-Month Open-Label Study
Maurizio Fava, Luca Pani, Sara De Martin, et al.
The Journal of Pain
|
February 5, 2013
Personalized medicine and opioid analgesic prescribing for chronic pain: opportunities and challenges
Stephen Bruehl, A Vania Apkarian, Jane C Ballantyne, et al.
The American Journal of Psychiatry
|
December 22, 2021
REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial
Maurizio Fava, Stephen Stahl, Luca Pani, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 63) with videos related to
Sort By:
Page
of 7
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
September 24, 2011
Cav1.2 L-type Ca²⁺ channels mediate cocaine-induced GluA1 trafficking in the nucleus accumbens, a long-term adaptation dependent on ventral tegmental area Ca(v)1.3 channels
Kathryn Schierberl, Jin Hao, Thomas F Tropea, et al.
International Journal of Molecular Sciences
|
October 27, 2022
Esmethadone (REL-1017) and Other Uncompetitive NMDAR Channel Blockers May Improve Mood Disorders via Modulation of Synaptic Kinase-Mediated Signaling
Stephen M Stahl, Sara De Martin, Andrea Mattarei, et al.
NIH Consensus and State-Of-The-Science Statements
|
March 1, 2008
NIH consensus development statement on hydroxyurea treatment for sickle cell disease
Otis W Brawley, Llewellyn J Cornelius, Linda R Edwards, et al.
Pharmaceuticals (Basel, Switzerland)
|
August 26, 2022
Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors
Ezio Bettini, Stephen M Stahl, Sara De Martin, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
July 2, 2003
A conditional deletion of the NR1 subunit of the NMDA receptor in adult spinal cord dorsal horn reduces NMDA currents and injury-induced pain
Samantha M South, Tatsuro Kohno, Brian K Kaspar, et al.
European Archives of Psychiatry and Clinical Neuroscience
|
March 8, 2023
Esmethadone-HCl (REL-1017): a promising rapid antidepressant
Maurizio Fava, Stephen M Stahl, Sara De Martin, et al.
International Clinical Psychopharmacology
|
February 27, 2026
Depression severity and efficacy outcomes: post hoc analyses from a phase 3 trial of esmethadone for the adjunctive treatment of major depressive disorder with inadequate response to standard antidepressants
Clotilde Guidetti, George I Papakostas, Steven Stahl, et al.
The Journal of Clinical Psychiatry
|
February 25, 2025
Long-Term Safety and Efficacy of Esmethadone in Patients With Major Depressive Disorder: Findings From a 12-Month Open-Label Study
Maurizio Fava, Luca Pani, Sara De Martin, et al.
The Journal of Pain
|
February 5, 2013
Personalized medicine and opioid analgesic prescribing for chronic pain: opportunities and challenges
Stephen Bruehl, A Vania Apkarian, Jane C Ballantyne, et al.
The American Journal of Psychiatry
|
December 22, 2021
REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial
Maurizio Fava, Stephen Stahl, Luca Pani, et al.
Page
of 7